BPC-157 Capsules vs Vials
We stock BPC-157 both ways. A capsule is a finished solid form; a vial is freeze-dried powder you reconstitute. What changes is the handling, the storage and the paperwork — and for this particular compound there is a published stability finding worth knowing about.
What arrives, in each case
A vial contains BPC-157 as a lyophilised powder — freeze-dried, which is the stable form for storage and shipping. It is reconstituted with bacteriostatic water before it is a solution at all. Our vial is 10mg.
Capsules arrive finished. There is no reconstitution step, no water to buy, no concentration to work out, and nothing to keep cold once it is in solution — because it never is.
That is the practical difference and it is mostly about steps. The reconstitution calculator and how to reconstitute peptides cover the vial route; the capsule route has nothing to cover.
Side by side
| Capsules | 10mg vial | |
|---|---|---|
| State on arrival | Finished solid dose form | Lyophilised powder |
| Reconstitution | None | Required, with bacteriostatic water |
| Consumables needed | None | Water, syringes, swabs |
| Storage before opening | Cool, dry, out of light | Cool, dry, out of light |
| Storage after preparing | Unchanged | Refrigerated, and it has a limited life — see storage |
| Quantity per unit | Stated per capsule on the label | 10mg in the vial |
| Certificate of analysis | On request | On request |
| Starter kit available | Not needed | Yes |
The stability finding, and what it does and does not say
BPC-157 has an unusual property in the published record, and it is the reason the oral form of this compound is discussed at all rather than dismissed.
The paper reporting its clinical-trial programme for inflammatory bowel disease — run under the development codes PL-10, PLD-116 and PL 14736 — also reports its stability in human gastric juice (PMID 17186181). Peptides are generally degraded by gastric conditions, which is why most are not supplied as oral forms at all. This one has a published finding on that specific point.
Two limits on that, both important. It is a stability finding, not an equivalence finding: that a molecule survives a condition is not a statement that two formats deliver the same thing, and the paper does not make that claim. And it is specific to BPC-157. It does not extend to TB-500 or to any other compound in the catalogue, which is one reason TB-500 is stocked as a vial only — see BPC-157 vs TB-500.
Why most peptides are vials
Freeze-drying is the answer. A lyophilised powder is stable at ordinary temperatures for a long period; the same peptide in solution is not. Supplying powder and leaving the solution to be made up at the point of use is what makes a peptide shippable at all, and it is why the vial is the default across the range — what are peptides goes into the chemistry.
The compounds we offer as capsules are the exceptions, and each is an exception for its own reason: BPC-157, KPV, 5-Amino-1MQ and the Wolverine Stack. Everything available that way is listed on peptide capsules.
What the formats do not change
Neither format carries a marketing authorisation. A capsule looks more like a medicine than a vial does, and that appearance means nothing at all: both are unlicensed research compounds, both carry an analytical specification rather than a Summary of Product Characteristics, and both are supplied for laboratory research use only.
Purity is determined the same way for both, with a certificate of analysis available on request. The format is a presentation decision. It is not a regulatory category and it is not a quality grade.
Supply note. Peptiq supplies research compounds for laboratory research use only. We are not a pharmacy and we do not supply licensed medicines. Where a licensed medicine is named on this page it is named to draw a distinction, not because we sell it, and nothing here is guidance on use.
Frequently asked questions
Do you supply BPC-157 as capsules and as a vial?
Yes, both. The vial is 10mg of lyophilised powder requiring reconstitution with bacteriostatic water. The capsules arrive as a finished solid form with the quantity per capsule stated on the label.
Is there published research on oral BPC-157?
The paper reporting BPC-157's inflammatory bowel disease trial programme also reports its stability in human gastric juice (PMID 17186181). That is a stability finding. It is not a finding that the two formats are equivalent, and it is specific to BPC-157.
Which format needs bacteriostatic water?
Only the vial. Capsules arrive finished and need no reconstitution, no water and no syringes.